ALLR
Allarity Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.42
−0.70%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.5x
Market Cap
$22.59M
MomentumView details →
1D Return
−0.70%
YTD Return
+33.33%
RSI (14)
60.1
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.5x
Market Cap
$22.59M
RSI (14)
60.1
MomentumView details →
1D Return
−0.70%
YTD Return
+33.33%
SummaryUpdated Jun 1, 2026
Allarity Therapeutics, Inc. (NASDAQ:ALLR) is a clinical-stage biopharmaceutical company founded in 2004 and headquartered in Cambridge, Massachusetts. The company went public in December 2021 and focuses on developing oncology therapeutics using proprietary drug response predictor technology to create companion diagnostics. Allarity operates in the highly specialized field of precision oncology, where treatments are tailored to individual patients based on their likelihood to respond to specific cancer drugs.
Similar companies
Latest newsMore news →
Allarity Therapeutics reported its Q2 2026 financial results, with zero revenue, a net loss of $3.4 million, and diluted EPS of -$0.21, ending the quarter with $26.9 million in cash and restricted cash.22d agoAllarity Therapeutics, Inc. appointed Thomas H. Jensen as Chief Executive Officer, effective June 1, 2026, with compensation including a monthly fee, annual bonus capped at 60% of monthly fees, and severance of 12 months of the monthly fee upon termination for convenience.95d ago